Astragali and adjuvant components, was studied for the treatment of chronic viral hepatitis in 116 patients; 92 patients were given other drugs in regular clinical use for viral hepatitis (controls). The clinical efficacy of AC was significantly better in AC-treated patients than in controls. Negative seroconversions of hepatitis B virus (HBV) antigen e and HBV DNA were also significantly higher in AC-treated patients than in controls. Of eight duck viral hepatitis B models infected with duck hepatitis B virus (DHBV) and treated with AC, three showed negative seroconversion of DHBV DNA and serum DHBV DNA levels significantly decreased after AC administration compared with the controls; DHBV DNA was negative in biopsied liver tissue by in situ hybridization and immunohistochemistry in two ducks treated with AC. Pathological changes were milder in ACtreated ducks than in controls. These results indicate that AC may promote recovery from viral hepatitis and inhibit HBV replication.
Introduction
Chinese herbs are widely and extensively used in the control of viral hepatitis and are sometimes very effective clinically. Radix Astragali is one of the main invigorating drugs in Chinese traditional medicine; it is claimed to expel pathogenic toxins from blood, regulate liver function and activate the function of the spleen. 1 Some reports have indicated that it can balance serum hormone levels and improve liver function in patients with chronic viral hepatitis. 2, 3 In order to increase the therapeutic efficiency of Radix Astragali, we designed Astragali compound (AC) of which Radix Astragali is the main active component. Other, adjuvant components of AC include Bupleurum chinense DC, Radix Salviae miltiorrhiza, Curcumae, Paeoniae Radix and Peony Radix. The clinical effects of AC in chronic hepatitis B patients and its experimental effects in a duck hepatitis B model were investigated in the present study. In the animal model, Phyllanthus niruri was used as a control drug as it has been reported to inhibit the replication of hepatitis B virus (HBV). 4 LL Tang, JF Sheng, CH Xu et al.
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Patients and methods
HUMAN CLINICAL STUDY
All patients were diagnosed according to the standards drafted by The 6th National Conference on Liver Diseases and The 2nd China-Indonesia Joint Symposium on Hepatobiliary Diseases 5 and were randomly allocated into two groups: a treatment group that was to be given AC and a control group to be given control drugs (see below).
Clinical symptoms (fatigue, anorexia, abdominal distension, jaundice, etc.) were recorded. Blood samples were taken before and immediately after the 2-month treatment period in all patients, and serum was separated and stored at −20°C until used for determination of liver function (alanine transferase and serum bilirubin), serum HBV markers, HBV DNA, anti-hepatitis C (HCV) and HCV RNA. The efficacy of treatment was classified into three categories: (i) obvious efficacy (OE) was the disappearance of clinical symptoms and the full recovery of liver function; (ii) efficacy (E) was the improvement of clinical symptoms and an improvement of > 50% in liver function tests; and (iii) no efficacy was no change or deterioration of symptoms and liver function. Total efficacy was OE plus E.
Ethics approval of the study was obtained from Zhejiang University. Patients provided informed consent prior to taking part in the study both in writing and verbally.
ANIMAL MODEL STUDY
A duck hepatitis B model was used in the present study for comparison with the human clinical study and to obtain liver pathological data. All ducks were bred and reared at Zhejiang Academy of Agricultural Science. All experiments were performed in compliance with the Zhejiang University institutional guidelines for the use of animals in research. All ducks were given free access to food and water in the study.
Thirty 1-day old ducks born of Cherry Valley parents that were negative for duck HBV (DHBV) DNA and duck hepatitis B surface antigen (DHBsAg) were injected peritoneally with 100 µl DHBV-positive serum, containing 1.8 × 10 8 copies of DHBV DNA. The DHBV clone plasmid PBR322 was provided by the Department of Microbiology, Shanghai Medical University. Serum levels of DHBV DNA and DHBsAg were determined 2, 4 and 8 weeks after injection. At 8 weeks, 22 ducks tested positive for serum DHBV DNA and DHBsAg and were randomly allocated to three groups: a treatment group that was given AC (n = 8), (ii) a treatment control group that was given Phyllanthus niruri (PN; n = 7) and an untreated control group (n = 7).
Blood samples were taken from the ducks before the treatment period, 1 and 2 months after the beginning of treatment and 15 days after the end of treatment, and serum was separated and stored at −20°C until used for determination of DHBV DNA or DHBsAg levels. The ducks were killed 15 days after the end of treatment and liver samples were fixed in 10% neutral formalin solution for examination of pathological changes and determination of DHBsAg and DHBV DNA.
TREATMENTS
Human clinical study
In the human study, the daily dose of AC was prepared as a powder at the Pharmaceutical Factory of the School of Medicine, Zhejiang University, consisting of Radix Astragali 45 g, Radix Bupleurum chinense DC 12 g, Radix Salviae miltiorrhizae 20 g, Curcumae 12 g, Peony Radix 12 g and Paeoniae Radix 15 g. For each patient in the AC treatment group the daily dose was divided into three bags. One bag was put into a cup and hot water was poured onto it and, after 5 -10 min infusing, the patient drank all the water LL Tang, JF Sheng, CH Xu et al.
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after meals. This was carried out three times daily for 2 months. Patients in the control group took a bag containing 77 mg of silibinin (Fourth Pharmaceutical Factory, Beijing, China), 40 mg oleanolia acid (South of Zhejiang Pharmaceutical Factory, Hangzhou, China) and 2 g Yi-Gan-Ling (Jilin Liaohe Traditional Chinese Medicine Factory, Changchun, China) with hot water (similarly to the AC group) three times daily for 2 months. No other drugs were used during the treatment period.
Animal model
The daily dose of AC used in the duck hepatitis B model was one-third of that in human patients because, according to our unpublished data, one-third dose of that in human patients was most suitable for the duck hepatitis B model. The treatment control group was given PN at a daily dose of 1.5 g. Both drugs were well mixed into the ducks' feed; half the daily dose was given in the morning and half in the evening for 2 months. 7 and serum HCV RNA was detected by reverse transcriptase (RT)-PCR. 8 Liver enzymes, including alanine transferase and serum bilirubin, were determined using an autobiochemical analysis machine (AU400; Olympus, Tokyo, Japan). Serum DHBsAg was detected by dot enzyme immunoassay (HBsAg testing kit; Abbott, Delkenheim, Germany), and serum DHBV DNA was detected using a dot hybridization kit (Boehringer Mannheim, Mannheim, Germany), according to the manufacturer's instructions.
LABORATORY ANALYSES
Pathological lesions were diagnosed and analysed by a pathologist. Detection of DHBV DNA and DHBsAg in hepatic tissue was by in situ hybridization and immunohistochemistry, respectively. 9 Inflammation was assessed by haematoxylin-eosin (HE) and van Gieson (VG) staining.
STATISTICAL ANALYSIS
The χ 2 test was used to analyse the human data and the modified t-test was used for the animal data. A P-value of < 0.05 was considered significant.
Results
HUMAN CLINICAL STUDY
A total of 208 chronic viral hepatitis B patients, 116 in the AC treatment group and 92 in the control group were included in the study. Their overall mean age was 38 years (range 25 -56 years). Patients in the two groups had mild fatigue and loss of appetite, their serum alanine transferase level was 1 -5 times above normal and serum bilirubin was less than two times above the normal level. In the AC treatment group, 94 patients were positive for HBsAg and HBcAb, nine were positive for only HBcAb and 13 were negative for both of these HBV markers. Of the 94 patients positive for both HBsAg and HBcAb, 47 were also positive for HBeAg and 50 of 62 patients tested for HBV DNA were positive for viral DNA. Six of the 12 HBVnegative patients were positive for anti-HCV and one was positive for HCV RNA. All 92 patients in the control group were positive for both HBsAg and HBcAb, and 42 were positive for HBeAg; 32 of the 54 control patients tested for HBV DNA were positive for viral DNA.
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The clinical efficacy of the AC treatment was significantly better than the control, as shown in Table 1 (P < 0.01). The proportion of negative seroconversions of HBeAg and HBV DNA were also significantly higher in the AC group than in the control group (P < 0.01 and P < 0.05 respectively), indicating that AC inhibited replication of hepatitis B virus (Table 2 ). In addition, three of the six HCV-positive patients, including the patient with HCV RNA, showed HCV seroconversion after AC treatment.
There were no obvious side effects during the clinical experiments. Two patients felt mild abdominal distension, but this disappeared after the daily dose had been decreased in such a way as to maintain the same total dose. All patients completed the course of therapy.
ANIMAL MODEL STUDY
Seven of the eight ducks treated with AC completed the course of treatment and three of these (37.5%) ducks showed negative DHBV DNA seroconversion after treatment. One of the ducks given the AC treatment died after 5 weeks and one of the seven ducks treated with PN died after 4 weeks; both deaths were because of accidental injury. No negative seroconversion was found in either the PN group (treatment control) or the untreated control group. Serum levels of DHBV DNA were significantly lower after AC treatment than before treatment (P < 0.05), whereas the levels did not change significantly over time in the PN group or untreated control group (Table 3) .
The 20 ducks that finished the course of the study (seven in the AC group, six in the PN group and seven in the untreated group) underwent liver biopsy and DHBsAg and DHBV DNA were detected in all samples. Positivity for DHBsAg in the liver was found
Treatment group Total efficacy b Obvious efficacy b Efficacy b No efficacy b
Astragali compound (n = 116) 105 (90.5%)** 76 (65.5%)** 29 (25.0%) 11 (9.5%)** Control (n = 92) a 64 (69.9%) 26 (28.3%) 38 (41.3%) 28 (30.4%) **P < 0.01 compared with control group. a The control group was treated with silibinin, oleanolia acid and Yi-Gan-Ling. b Obvious efficacy, disappearance of clinical symptoms and full recovery of liver function; efficacy, improvement of clinical symptoms and improvement of > 50% in liver function tests; no efficacy, no change or deterioration of symptoms and liver function; total efficacy, obvious efficacy plus efficacy. LL Tang, JF Sheng, CH Xu et al.
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in all seven ducks in the AC group, five of the six ducks in the PN group and five of the seven in the untreated group. Yellow-brown granules of DHBsAg scattered in the cytoplasm of hepatocytes were seen under the microscope. Two ducks in the AC group, none in the PN group and one in the untreated group were negative for DHBV DNA in liver tissue, which was also seen microscopically as yellow-brown granules scattered in the cytoplasm of hepatocytes. The DHBV DNA and DHBsAg data did not differ significantly among the three groups. The HE and VG staining indicated mild or moderate infiltration of inflammatory cells and no acidophilic necrosis or bridging necrosis was detected by HE in the liver of all seven untreated ducks. The VG staining showed mild or moderate collagen proliferation and thickening of collagen fibres in the portal area in the liver of all seven untreated ducks. Three ducks in the AC group showed mild infiltration of inflammatory cells (lymphocytes, monocytes, etc.) in the interstitium, one duck showed mild collagenous proliferation, and the remaining three ducks showed no obvious abnormality. Five ducks in the PN group showed mild infiltration of inflammatory cells accompanied by mild collagenous proliferation; only one duck in the PN group appeared to have normal liver tissue.
Discussion
In traditional Chinese medicine, chronic hepatitis is considered to be caused by 'Zheng Xu Xie Shi' (i.e. body resistance is weakened and the pathogen invades). Based on the principle of 'fu zheng qu xie' (strengthening the body's resistance against pathogenic factors), we have used Radix Astragali previously to treat chronic hepatitis and found that it could regulate the levels of many serum hormones and improve liver function, 3,10 but the clinical effect was small. Some adjuvant substances, namely Bupleurum chinense DC, Radix Salviale miltiorrhizae, Curcumae, Peony Radix and Paeoniae Radix, that have the effects of 'shu gan jie yu' (promoting liver function) and 'huo xue hua yu' (protecting the body from coagulation) have been added to Radix Astragali to formulate AC for use in clinical and laboratory studies. It has been reported that Bupleurum chinense DC promotes liver function in rats with acute toxic hepatic damage. 11 Radix Salviae miltiorrhizae is able to protect the hepatocytes of rats from toxic injury and this effect may be related to liver microsomal cytochrome P450, 12, 13 and also that Curcumae and Paeoniae Radix can protect the liver from hepatocyte necrosis and fibrosis induced by carbon tetrachloride. 14, 15 In the present work, the use of AC in the treatment of patients with chronic viral
Before treatment
After treatment Treatment group (log −1 pg/10 µl) (log −1 pg/10 µl)
Astragalus compound (n = 8) 1.68 ± 0.74 0.62 ± 0.36* Phyllanthus niruri (treatment control, n = 7)
1.80 ± 0.78 1.40 ± 0.58 Untreated control (n = 7)
1.67 ± 1.07 1.80 ± 0.78 *P < 0.05 compared with before treatment and with the P. niruri and control groups.
TABLE 3: Comparison of the effects of Astragali compound compared with controls on serum duck hepatitis B virus (DHBV) DNA levels in a duck model following peritoneal injection with DHBV-positive serum (mean ± SD)
• Received for publication 5 January 2009 • Accepted subject to revision 7 January 2009 • Revised accepted 22 April 2009 Copyright © 2009 Field House Publishing LLP hepatitis B showed marked clinical efficacy compared with the control. Our pathological studies in a duck model indicated that AC might have beneficial effects in terms of reduced degeneration and necrosis of liver tissue, decreased infiltration of inflammatory cells, and inhibition of the formation of collagen fibres, although further studies with greater numbers are needed to be able to reach this conclusion with certainty. The present clinical and animal experiments indicated that AC may inhibit HBV replication to some degree, although the mechanism by which this occurs is currently unclear and should be investigated in further studies.
